Ptc Therapeutics (PTCT) Operating Leases (2019 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Operating Leases of $87.5 million for Q2 2026, up 5.51% year-over-year from $83.0 million in Q2 2025, and down 2.82% quarter-over-quarter from $90.1 million in Q1 2026.
Ptc Therapeutics (PTCT) Operating Leases (2019 - 2026) Analysis & Trends
Ptc Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $87.5 million for Q2 2026.
- In Q2 2026, Operating Leases rose 5.51% year-over-year to $87.5 million; the TTM figure through Jun 2026 stood at $87.5 million (up 5.51% YoY), while the FY2025 annual figure was $93.6 million, up 24.87% from the prior year.
- Operating Leases for Q2 2026 stood at $87.5 million, down from $90.1 million in the prior quarter.
- The five-year high for Operating Leases was $146.3 million in Q2 2022, with the low at $74.9 million in Q4 2024.
- The 5-year median for Operating Leases is $97.3 million (2023), against an average of $99.9 million.
- The sharpest annual moves came in 2022 and 2025: Operating Leases surged 91.37% in 2022, then retreated 28.8% in 2025.
- Ptc Therapeutics' Operating Leases stood at $100.9 million in 2022, then decreased by 3.21% to $97.6 million in 2023, then declined by 23.23% to $74.9 million in 2024, then gained by 24.87% to $93.6 million in 2025, then decreased by 6.46% to $87.5 million in 2026.
- Business Quant data shows PTCT's Operating Leases at $87.5 million in Q2 2026, $90.1 million in Q1 2026, and $93.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.53 Mn |
| Mar 31, 2026 | 90.07 Mn |
| Dec 31, 2025 | 93.58 Mn |
| Sep 30, 2025 | 95.49 Mn |
| Jun 30, 2025 | 82.96 Mn |
| Mar 31, 2025 | 85.02 Mn |
| Dec 31, 2024 | 74.95 Mn |
| Sep 30, 2024 | 82.77 Mn |
| Jun 30, 2024 | 92.83 Mn |
| Mar 31, 2024 | 119.41 Mn |
| Dec 31, 2023 | 97.63 Mn |
| Sep 30, 2023 | 111.39 Mn |
| Jun 30, 2023 | 110.62 Mn |
| Mar 31, 2023 | 110.04 Mn |
| Dec 31, 2022 | 100.86 Mn |
| Sep 30, 2022 | 102.12 Mn |
| Jun 30, 2022 | 137.35 Mn |
| Mar 31, 2022 | 79.80 Mn |
| Dec 31, 2021 | 73.62 Mn |
| Sep 30, 2021 | 74.82 Mn |